Theodorus I

In Theodorus I five exits were realised. These revenues largely compensate the initial ULB investments. The eight remaining participations should allow to generate a significant profit. 

Exits
Spin-offs Current situation – perspectives 
DNAVision

Theodorus sold its shares to the CEO and a new investor.
www.dnavision.com

Euroscreen

Euroscreen focuses on the identification and development of drugs for unmet medical needs, based on small molecules. Euroscreen realised already a partial exit.

Euroscreen focuses on the identification and development of drugs for unmet medical needs, based on small molecules. Euroscreen realised already a partial exit. The clinical development is accelerated by a recent capital increase of more than € 10 Mn.
www.euroscreen.be 

Henogen

Henogen developed a CMO (Contract Manufacturing Organisation) activity for high added value biotechnological products. Henogen was sold in 2008 to Novasep.
www.novasep.com

H-Phar

H-Phar developed a candidate-drug against AIDS. Theodorus sold its shares to the management.
www.h-phar.com

Lambda-X

Lambda-X was incorporated in 2006 and develops, produces and commercialises optical instruments, mainly for spatial applications. Theodorus sold its shares to the management.
www.lambda-x.com

 

Still in portfolio
Spin-offs Current situation – perspectives
Bone Therapeutics

Bone realised a capital increase of € 9.5 Mn in January 2011 to accelerate its development and raised an additional € 2.5 Mn end 2011 to finance the construction of its production facilities in Gosselies. Bone Therapeutics raised more than € 7.5 Mn in November 2012 to continue to accelerate its clinical development and to prepare
in optimal conditions an important financial and/or industrial deal.

Bone Therapeutics is currently implementing two Phase 3 trials for autologous products and one Phase 1 -2A trial for an allogeneic product. 
www.bonetherapeutics.com
Euro Heat Pipes

Euro Heat Pipes develops, produces and commercialises two-phase thermoregulating systems for applications in space.
www.ehp.be

Theodorus II et III

The ULB invested, via Theodorus I, in Theodorus II and III. 

Masthercell, an innovative cGMP manufacturing platform, has been incorporated for the clinical and commercial production of cellular therapy products in Europe. Production has started up early 2014 after GMP accreditation has been obtained. First contracts have been signed, several others are in final negociation.
The company plans an additional development in the USA. This development will be financed by an additional € 2 Mn, raised in September 2014.

www.masthercell.com

Calyos is a spin-out of Euro Heat Pipes, which historically raised € 3.4 Mn in two rounds. It develops, produces and commercialises two-phase thermoregulating systems for non-space applications. The first one has been integrated in Alstom underground trains and the start of commercialisation is planned in 2014. The second will be integrated in high power computers in the short term.

Calyos is currently raising new funds to accelerate its commercial and industrial development.
www.calyos-tm.com 

 

Heritage Management Services (HMS) offers services to any responsible of development projects in Africa who has to determine the impact of the project on the cultural heritage of the country or countries involved. HMS aims at limiting this impact without slowing down construction schedules.
www.hms-archaeology.com

 Domobios

Domobios develops and commercialises products to eradicate domestic pests. The first product against house dust mites, Acar’Up, is available in pharmacy.
www.domobios.com 

 

Activities stopped
Spin-off Result
Target hit

Target Hit developed lipidic structures for the targeted delivery of drugs to specific organs. 

Unibioscreen

Unibioscreen, incorporated in 1999, developed oncologic drugs of natural origin. Unibioscreen had two candidate-drugs in Phase 1.

 Aliwen

Aliwen was specialised in consulting on trees, parcs, forests, ...

 BruCells

Brucells, incorporated in 2001, developed antitumoral cell therapy products based on dendritic cells.

 

 

Production has started up early 2014 after GMP accreditation has been obtained. First contracts have been signed, several others are in final negociation.

The company plans an additional development in the USA. This development will be financed by an additional € 2 Mn, raised in September 2014.

Created by Comfi